News
-
-
-
-
COMMUNIQUÉ DE PRESSE
HBM portfolio company Yellow Jersey Therapeutics to be acquired for USD 1.25 billion
HBM Healthcare Investments announces Yellow Jersey Therapeutics acquisition by Johnson & Johnson for USD 1.25 billion. Transaction increases NAV per HBM share by CHF 8.70 (+3.5%) with expected cash inflow of USD 78 million -
-
-
COMMUNIQUÉ DE PRESSE
HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America
Swixx BioPharma, a portfolio company of HBM Healthcare Investments, expands into Latin America with acquisition of Laboratorios Biopas Group, boosting sales and profits -
-
-
COMMUNIQUÉ DE PRESSE
HBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin America
HBM Healthcare Investments' portfolio company Swixx BioPharma acquires Laboratorios Biopas Group in Latin America, boosting sales and profits. The strategic acquisition expands Swixx's footprint and market presence
